WCG
CRSP icon

Weaver Consulting Group’s CRISPR Therapeutics CRSP Stock Holding History

Weaver Consulting Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-150
Closed -$13K – 289
2020
Q3 		$13K Hold
150
– – 0.01% 486
2020
Q2 		$11K Buy
+150
New +$8.77K 0.01% 498

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Weaver Consulting Group's CRSP Position: Q4 2020 in Review

Weaver Consulting Group sold out of CRISPR Therapeutics (CRSP) in Q4 2020, closing a stake of 150 shares — an estimated $13K sold.

Weaver Consulting Group first reported a position in CRSP in Q2 2020 and held it in 2 quarters. The position peaked at $13K in Q3 2020. 412 funds tracked by Wall St. Rank hold CRSP as of Q4 2020.

  • Weaver Consulting Group reported no remaining CRISPR Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Weaver Consulting Group sold 150 CRISPR Therapeutics shares in Q4 2020, an estimated $13K.
  • Weaver Consulting Group first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 2 quarters.
  • Weaver Consulting Group's CRISPR Therapeutics position peaked at $13K in Q3 2020.
  • 412 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.